Skip to main content

Table 1 Patient characteristics

From: Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

  All (n = 48) Bev group (n = 17) Non-Bev group (n = 31) p value
Age (years) 67.5 (65.0–73.0) 67.0 (66.0–73.0) 68.0 (66.5–73.0) 0.75
Sex (male, %) 40 (83.3) 17 (100) 23 (74.2) 0.038
Smoking status     0.08
 Current or former 42 (87.5) 17 (100) 25 (80.6)  
 Never 6 (12.5) 0 (0) 6 (19.4)  
 Previous steroid therapy 6 (12.5) 2 (11.8) 4 (12.9) 1.00
ECOG PS     0.37
 0–1 40 (83.3) 13 (76.5) 27 (87.1)  
 ≥2 8 (16.7) 4 (23.5) 4 (12.9)  
Stage     1.00
 III 9 (18.7) 3 (17.6) 6 (19.4)  
 IV 39 (81.3) 14 (82.4) 25 (80.6)  
Classification of ILD     1.00
 IIPs 45 (93.7) 16 (94.1) 29 (93.5)  
 Non-IIPs 3 (6.3) 1 (5.9) 2 (6.5)  
ILD pattern     1.00
 UIP pattern 24 (50.0) 9 (52.9) 15 (48.4)  
 Non-UIP pattern 24 (50.0) 8 (47.1) 16 (51.6)  
SpO2 at rest (%) 96.0 (96.0–97.0) 96.0 (95.0–97.0) 96.0 (96.0–97.0) 0.43
FVC (% predicted) 88.5 (79.5–100) 87.5 (78.5–99.5) 90.0 (81.0–100) 0.85
LDH (U/L) 220.0 (194.8–254.0) 228.0 (205.0–253.0) 211.0 (194.5–252.5) 0.48
KL-6 (U/ml) 800.0 (518.5–1190.0) 828.5 (591.0–1311.0) 778.0 (454.0–1120.0) 0.27
CRP (mg/dl) 0.9 (0.3–2.0) 0.9 (0.7–2.3) 0.9 (0.2–1.2) 0.44
First-line regiments     0.96
 CDDP + PEM 11 (22.9) 4 (23.5) 7 (22.6)  
 CBDCA + PEM 25 (52.1) 10 (58.8) 15 (48.3)  
 PEM 4 (8.3) 1 (5.9) 3 (9.7)  
 CBDCA + PTX 8 (16.7) 2 (11.8) 6 (19.4)  
 PEM-containing regiments 40 (83.3) 15 (88.2) 25 (80.6) 0.69
 First-line related AE-ILD 7 (14.5) 0 (0) 7 (22.6) 0.041
  1. Data are expressed as group median (interquartile range) or number of patients (%). The p values refer to comparisons between the Bev and non-Bev groups. ECOG PS Eastern Cooperative Oncology Group performance status, ILD interstitial lung disease, IIPs idiopathic interstitial pneumonias, UIP usual interstitial pneumonia, FVC forced vital capacity, SpO2 percutaneous oxygen saturation, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, CRP C-reactive protein, CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin, PTX paclitaxel, AE-ILD acute exacerbation of interstitial lung disease